Lyell Immunopharma, Inc. Profile Avatar - Palmy Investing

Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to over…

Biotechnology
US, South San Francisco [HQ]

News

Theses · Events · Sentiments
End of LYEL's Analysis
CIK: 1806952 CUSIP: 55083R104 ISIN: US55083R1041 LEI: - UEI: -
Secondary Listings
LYEL has no secondary listings inside our databases.